| Literature DB >> 34731105 |
Pincao Gao1,2,3, Fang Tang2, Weiguo Liu1, Kai He2, Yu Mo1.
Abstract
BACKGROUNDS: Chronic obstructive pulmonary disease (COPD) is a common, preventable disease of airflow limitation that accounts for the third leading deaths of any disease process in the worldwide. Health benefits of liuzijue qigong (LQG) on patients with stable COPD has been assessed. This study was designed to perform a systemic review and meta-analysis of the effect of Liuzijue breathing exercise on patients with stable COPD.Entities:
Mesh:
Year: 2021 PMID: 34731105 PMCID: PMC8519198 DOI: 10.1097/MD.0000000000027344
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.889
Figure 1The flow diagram of the selection process.
The detailed characteristics of each selected study.
| Duration of intervention | ||||||||||
| Author, Year | Region language | Sample (L/C) | Mean age /Year (L/C) | Intervention program (L/C) | Frequency (weekly) | Time (min) | Duration (month) | Outcome | Adverse event | Jadad score |
| Fang DP 2012 | Fuzhou, China, (Chinese) | 61/60 | 71.75/73.10 | L=Routine health advice+LQG C=Routine health advice+conventional breathing exercise | 7 | 30 | 6 | Dyspnea score; Exercise capacity (6-MWD) | No | 3 |
| Chen JX 2009 | Fuzhou, China, (Chinese) | 31/29 | 70.16/71.52 | L=Routine health +LQG C=Routine health+ breathing exercise | 7 | 30 | 3 | FEV1,; FVC; FEV1/FVC (%); 6MWD | No | 3 |
| ZhangMM 2019 | Shanghai, China, (Chinese) | 67/71 | 71.0/70.4 | L=oxygen therapy +drug+LQG C= oxygen therapy+drug | 21 | 30 | 12 | mMRC; AECOPD; PaCO2; 6MWD; SGRQ | No | 2 |
| Sun N2019 | Qingdao, China, (Chinese) | 56/56 | 65.45/64.78 | L=conventional drugs + health advice+ Lip and abdominal breathing +LQG C=Conventional drugs +health advice+ Lip and abdominal breathing exercise | 14 | 30 | 6 | FEV1; FEV1%; 6MWD; SGRQ | No | 3 |
| Deng LJ 2018 | Fuzhou, China, (Chinese) | 28/26 | 72.37/72.60 | L=Conventional drugs +LQG C=Conventional drugs + breathing exercise | 5 | 30 | 3 | mMRC; 6MWD; SGRQ | No | 4 |
| Wu WB 2018 | Shanghai, China, (English) | 16/17 | 67/66 | L=conventional treatment+LQG C=conventional treatment+no exercise | 6 | 40 | 6 | FEV1;MMEF, FEV1%; FEV1/FVC (%); 6MWD; 30S ssT, repetitions; Handgrip strength; SGRQ | No | 5 |
| Jiang MN 2017 | Changsha, China, (Chinese) | 33/32 | 63.66/60.64 | L=conventional treatment+LQG C=conventional treatment+breathing exercise | 7 | 30 | 3 | FVC, FEV1%; 6MWD; CAT | No | 3 |
| ZhangWX 2009 | Fuzhou, China, (Chinese) | 21/19 | 71.76/73.32 | L=routine health+LQG C=routine health | NS | NS | 3 | 6MWD | No | 2 |
| Zhu Z 2011 | Nanjing, China, (Chinese) | 20/22 | 60.85/60.85 | L=conventional treatment+LQG C=conventional treatment | NS | NS | 3 | FEV1; FEV1%; FEV1/FVC (%) | No | 2 |
| Chen JX 2008 | Fuzhou, China, (Chinese) | 21/19 | 71.76/73.32 | L=Routine health+LQG C=Routine health | NS | NS | 3 | MRC; FEV1; FEV1%; FEV1/FVC (%) | No | 3 |
| Li DX 2011 | Fuzhou, China, (Chinese) | 30/30 | 72.77/70.13 | L=conventional treatment+health advice+LQG C=conventional treatment+health advice+breathing exercise | 7 | 30 | 3 | FEV1; FEV1%; FEV1/FVC (%) Raw;sGaw;MIP;MEP | No | 3 |
| Chen FX 2015 | Fuzhou, China, (Chinese) | 30/32 | 76.53/76.59 | L=Conventional treatment+health advice+LQG C=conventional treatment+health advice | 5∼7 | 30 | 3 | FEV1; FEV1%; FEV1/FVC (%); IL-8, TNF-α, Fn | No | 4 |
| Lan Y 2016 | Luzhou, China, (Chinese) | 42/42 | 67.24/67.02 | L=drug+LQG C=drug | 10 | 60 | 3 | FEV1%;FEV1/FVC (%); CAT; | No | 2 |
| He JF 2019 | Beijing, China, (Chinese) | 30/30 | 66.26/63.20 | L=Conventional treatment+health advice+LQG C=conventional treatment+health advice | 14 | 10 | 6 | AECOPD; CAT; FEV1%;FVC FEV1/FVC (%); T lymphocyte subsets | No | 5 |
| Li R 2018 | Beijing, China, (Chinese) | 15/15 | 67.73/67.21 | L=conventional treatment+LQG C=conventional treatment+no exercise intervention | 3 | 60 | 3 | FEV1%; FVC; CAT, FEV1/FVC (%); | No | 3 |
| Wang LB 2015 | Shanghai, China, (Chinese) | 17/19 | 66.06/65.74 | L=conventional treatment+LQG C=conventional treatment | 6 | 20 | 6 | BMI, 6MWD; mMRC; FEV1% FEV1/FVC (%);SGRQ | No | 6 |
Figure 2Risk of bias summary: Review authors’ judgments of bias items for each included study.
Figure 3Meta-analyzes of the effect of liuzijue health qigong on mMRC compared with the control group as conducted in different intervention periods.
Figure 4Meta-analyzes of the effect of liuzijue health qigong on FEV1 (L) compared with the control group as conducted in different intervention periods.
Figure 5Meta-analyzes of the effect of liuzijue health qigong on FEV1 (%) compared with the control group as conducted in different intervention periods.
Figure 6Meta-analyzes of the effect of liuzijue health qigong on FEV1/FVC (%) compared with the control group as conducted in different intervention periods.
Figure 7Meta-analyzes of the effect of liuzijue health qigong on 6MWD compared with the control group as conducted in different intervention periods.
Figure 8Meta-analyses of the effect of liuzijue health qigong on Health-related quality (CAT, SGRQ) compared with the control group as conducted in different intervention periods.
Figure 9Funnel plot for evaluating the publication bias.